TrueBinding, Inc.
Small molecule therapeutics for neurodegenerative diseases, stroke, metabolic diseases, and oncology
- Sector
- Biotech
- Headquarters
- Foster City, CA
- Founded
- 2017
- Latest Form D
- $57.7M, Jul 2023
- Total capital
- $198M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $198M
- 4 Form D · last Jul 2023
- 40 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 36 pending · first 2022
- Rank in peer group#293 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$57.7M
- Private capital raisedForm D · SEC · 3rd filing$20.1M
- Private capital raisedForm D · SEC · 2nd filing$100M
- Private capital raisedForm D · SEC · 1st filing$19.7M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#293 · top 20%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Dongxu SunResearcherExecutive Officer, DirectorLinked by 1 patent
- Ke HongExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 40- PendingANTI-GAL3 Antibodies And Uses ThereofUSPTOApplication 19382093
- GrantedANTI-GAL3 Antibodies And Uses ThereofUSPTOUS 12,497,458
- PendingMethods Of Treating Inflammatory Diseases By Blocking GALECTIN-3USPTOApplication 19183662
Show all 40 patent records
- ANTI-GAL3 Antibodies And Uses ThereofAug 13, 2026 · Application 19382093Pending
- ANTI-GAL3 Antibodies And Uses ThereofDec 16, 2025 · US 12,497,458Granted
- Methods Of Treating Inflammatory Diseases By Blocking GALECTIN-3Jul 31, 2025 · Application 19183662Pending
- Treating Cancer By Blocking The Interaction Of TIM-3 And Its LigandMay 29, 2025 · Application 19044320Pending
- ANTI-GAL3 Antibodies And Methods Of UseMay 8, 2025 · Application 19017208Pending
- Methods Of Treating Inflammatory Diseases By Blocking GALECTIN-3Apr 22, 2025 · US 12,281,166Granted
- Treating Cancer By Blocking The Interaction Of TIM-3 And Its LigandFeb 18, 2025 · US 12,227,567Granted
- Methods Of Preventing Protein AggregationJan 23, 2025 · Application 18578450Pending
- Methods Of Treating Eye DiseaseOct 24, 2024 · Application 18637068Pending
- Treating Cancer By Blocking The Interaction Of TIM-3 And Its LigandJun 6, 2024 · Application 18354611Pending
- ANTI-GAL3 Antibody Formulations And Methods Of Use ThereofMay 16, 2024 · Application 18492607Pending
- Methods Of Treating Or Inhibiting Cardiovascular DiseasesSep 7, 2023 · Application 18053191Pending
- Antibodies That Disrupt The Interaction Of GAL3 And Insulin Receptor Or Integrins And Methods Of Use ThereofMar 30, 2023 · Application 17777573Pending
- ANTI-GAL3 Antibodies And Methods Of UseFeb 2, 2023 · Application 17812159Pending
- ANTI-GAL3 Antibodies And Methods Of Use For Insulin ResistanceDec 29, 2022 · Application 17834703Pending
- Antibodies And Blocking The Interaction Of Vista And Its Binding PartnerSep 8, 2022 · Application 17637778Pending
- ANTI-GAL3 Antibodies And Uses ThereofAug 30, 2022 · US 11,427,638Granted
- Methods And Compositions For Blocking Interaction Between Non-glycosylated PD-1 PolypeptidesNov 25, 2021 · Application 17041280Pending
- Treating Cancer By Blocking The Interaction Of Vista And Its Binding PartnerMar 25, 2021 · Application 16971559Pending
- Methods Of Preventing Protein AggregationApplication 63221395Pending
- ANTI-GAL3 Antibodies And Methods Of Use For Insulin ResistanceApplication 63202373Pending
- Methods Of Treating Inflammatory Diseases By Blocking GALECTIN-3Application PCTUS2021034096Pending
- ANTI-GAL3 Antibody Formulations And Methods Of Use ThereofApplication 63179879Pending
- ANTI-GAL3 Antibodies And Methods Of UseApplication PCTUS2021013136Pending
- ANTI-GAL3 Antibodies And Methods Of UseApplication 63122409Pending
- Antibodies That Disrupt The Interaction Of GAL3 And Insulin Receptor Or Integrins And Methods Of Use ThereofApplication PCTUS2020063134Pending
- ANTI-GAL3 Antibodies And Methods Of Use For Neurological Diseases And ProteopathiesApplication 63092069Pending
- Antibodies And Blocking The Interaction Of Vista And Its Binding PartnerApplication PCTUS2020048235Pending
- Treating Coronavirus-induced Diseases, Cytokine Release Syndrome, And Long-term Outcomes By Blocking GALECTIN-3Application 63030069Pending
- Antibodies That Disrupt The Interaction Of GAL3 And Cell Surface Receptors And Methods Of Use ThereofApplication 63024327Pending
- ANTI-GAL3 Antibodies And Uses ThereofApplication PCTUS2020015692Pending
- Antibodies That Disrupt The Interaction Of GAL3 And Tgf-b Receptor And Methods Of Use ThereofApplication 62960300Pending
- Antibodies That Disrupt The Interaction Of GAL3 And Insulin Receptor And Methods Of Use ThereofApplication 62944833Pending
- Treating Cancer By Blocking The Interaction Of Vista And Its Binding PartnerApplication 62893482Pending
- Methods And Compositions For Blocking Interaction Between Non-glycosylated PD-1 PolypeptidesApplication PCTUS2019025896Pending
- Methods And Compositions For Treating Neurodevelopmental DisordersApplication PCTUS2025034278Pending
- Treating Cancer By Blocking The Interaction Of Vista And Its Binding PartnerApplication PCTUS2019019186Pending
- Therapies With ANTI-GAL3 AntibodiesApplication 19116297Pending
- Methods And Compositions For Treating Neurodevelopmental DisordersApplication 63662737Pending
- Methods Of Treating Eye DiseaseApplication PCTUS2024024810Pending
Related companies, and why
- Candid TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Revolution MedicinesSimilar federal contract value in Biotech · null in contracts
- NovaBay PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
- Bright Peak TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Cognito Therapeutics Group, Inc.Similar federal contract value in Biotech · null in contracts
- BioAge LabsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .